V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
- 15 December 1993
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 90 (24) , 11518-11522
- https://doi.org/10.1073/pnas.90.24.11518
Abstract
Human monoclonal antibodies (mAbs) to two contiguous epitopes in the V3 loop of the human immunodeficiency virus type 1 (HIV-1) envelope have shown different effects on three distinct strains of the virus: neutralization, enhancement, or resistance to both processes. Only one amino acid in the mAb epitopes proximal to the crown of the V3 loop was different among these three strains. Substitution of this amino acid in the neutralizable strain with the amino acid of the neutralization-resistant strain or the enhanceable strain resulted in loss of both activities. The conversion of this single amino acid in the neutralization-resistant strain to that of the amino acid found in the neutralization-sensitive strain did not confer the ability for the virus to be neutralized. However, additional changes in neighboring amino acids in the V3 loop succeeded in conferring the neutralization capability. These observations indicate that one antibody species can exert three different effects on various HIV-1 strains. They could explain the emergence of neutralization "escape" variants in the presence of the neutralizing antibodies. Moreover, the results suggest caution in immunization of individuals with the envelope region from one strain since the antibodies induced may show a neutralizing effect against the homologous strain but enhancing effects against other unrelated strains.Keywords
This publication has 26 references indexed in Scilit:
- Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.Proceedings of the National Academy of Sciences, 1992
- Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.Proceedings of the National Academy of Sciences, 1989
- The Fc and not CD4 Receptor Mediates Antibody Enhancement of HIV Infection in Human CellsScience, 1989
- Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees.Proceedings of the National Academy of Sciences, 1989
- Antibody-Dependent Enhancement of Dengue Virus Growth in Human Monocytes as a Risk Factor for Dengue Hemorrhagic FeverThe American Journal of Tropical Medicine and Hygiene, 1989
- Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cellsJournal of Clinical Microbiology, 1988
- Antibody-Enhanced Infection by HIV-1 Via Fc Receptor-Mediated EntryScience, 1988
- Antibody-dependent enhancement of HIV infection.1988
- Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Proceedings of the National Academy of Sciences, 1988
- Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.Proceedings of the National Academy of Sciences, 1988